Anti-inflammation Therapy by Activation of Prostaglandin EP4 Receptor in Cardiovascular and Other Inflammatory Diseases
Authors:
- 1 February 2012
- journal article
- review article
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 59 (2) , 116-123
Abstract
Prostaglandin E2 constitutes a major cyclooxygenase-2-derived prostanoid produced at inflammatory sites. In vitro and in vivo data support its role as a modulator of inflammation. Prostaglandin E2 exerts anti-inflammatory effects by binding to one of its receptors, the prostaglandin E receptor 4 (EP4), thereby modulating macrophage and T lymphocyte functions that participate crucially in innate and adaptive immunity and tissue remodeling and repair. The activation of EP4 suppresses the release of cytokines and chemokines from macrophages and T cells, inhibits the proliferation and the activation of T cells, and induces T-cell apoptosis. Lack of EP4 in bone marrow–derived cells accelerates local inflammation in atherosclerotic and aneurysm lesions and increases the prevalence of aneurysm formation. An EP4 agonist promotes graft survival in allograft cardiac transplantation and dampens tissue damage after myocardial ischemia. Anti-inflammatory actions of EP4 agonism may benefit other inflammatory disorders, including colitis and gastric ulcers. By contrast, EP4 acts as a proinflammatory mediator in encephalomyelitis, skin inflammation, and arthritis by promoting T helper (Th) 1 differentiation and Th17 expansion. Overall, EP4 activation produces powerful anti-inflammatory responses in many experimental diseases, rendering EP4 agonists attractive agents to attenuate syndromes associated with inflammation.Keywords
This publication has 53 references indexed in Scilit:
- Deletion of EP4 on Bone Marrow–Derived Cells Enhances Inflammation and Angiotensin II–Induced Abdominal Aortic Aneurysm FormationArteriosclerosis, Thrombosis, and Vascular Biology, 2011
- Lack of EP4 receptors on bone marrow-derived cells enhances inflammation in atherosclerotic lesionsCardiovascular Research, 2010
- The Prostaglandin E2 E-Prostanoid 4 Receptor Exerts Anti-Inflammatory Effects in Brain Innate ImmunityThe Journal of Immunology, 2010
- A novel antagonist of the prostaglandin E2 EP4 receptor inhibits Th1 differentiation and Th17 expansion and is orally active in arthritis modelsBritish Journal of Pharmacology, 2010
- Macrophage EP4 Deficiency Increases Apoptosis and Suppresses Early AtherosclerosisCell Metabolism, 2008
- Pharmacological activation of the prostaglandin E2 receptor EP4 improves cardiac function after myocardial ischaemia/reperfusion injuryCardiovascular Research, 2008
- Prostaglandin E Receptor Type 4-associated Protein Interacts Directly with NF-κB1 and Attenuates Macrophage ActivationJournal of Biological Chemistry, 2008
- Origins of Prostaglandin E2: Involvements of Cyclooxygenase (COX)-1 and COX-2 in Human and Rat SystemsThe Journal of Pharmacology and Experimental Therapeutics, 2002
- Prostaglandin E2 Receptors, EP2 and EP4, Differentially Modulate TNF-α and IL-6 Production Induced by Lipopolysaccharide in Mouse Peritoneal NeutrophilsBiochemical and Biophysical Research Communications, 2000
- Prostaglandin modulation of development of cell-mediated immunity in cultureNature, 1980